Data Insights

Futibatinib by Otsuka Pharmaceutical for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Futibatinib by Otsuka Pharmaceutical for Metastatic Breast Cancer: Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Metastatic Breast Cancer

Data Insights

Futibatinib by Otsuka Pharmaceutical for Gastric Cancer: Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Gastric Cancer

Data Insights

Futibatinib by Otsuka Pharmaceutical for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Pancreatic Ductal Adenocarcinoma

Data Insights

Futibatinib by Otsuka Pharmaceutical for Solid Tumor: Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Solid Tumor

Data Insights

Futibatinib by Otsuka Pharmaceutical for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

Futibatinib by Otsuka Pharmaceutical for Urethral Cancer: Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Urethral Cancer. According to GlobalData, Phase...

Data Insights

Futibatinib by Otsuka Pharmaceutical for Esophageal Cancer: Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...

Data Insights

Futibatinib by Otsuka Pharmaceutical for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to...

Data Insights

Futibatinib by Otsuka Pharmaceutical for Endometrial Cancer: Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Data Insights

Futibatinib by Otsuka Pharmaceutical for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....